Competition
Competitive Position — Yatsen vs. the China beauty arena
Competitive Bottom Line
Yatsen's moat is real but narrow: a six-brand stack covering ¥30 to ¥1,500 price points, the highest gross margin (78.2%) in the listed beauty peer set, and an R&D intensity (3.2% of revenue, 269 patents, 1,049 R&D staff, joint labs with Sun Yat-sen University, Ruijin Hospital and the Chinese Academy of Sciences) that no Chinese small-cap competitor matches. Everything above the gross-margin line is enviable; everything below (66.3% selling & marketing) is the worst in the peer set — a 70%+ pricing-power moat being spent down 60%+ on traffic. Proya (SSE 603605) is the competitor that matters most: same domestic consumer wallet, same Tmall/Douyin shelf, 2.4× Yatsen's revenue, mid-teens operating margin, and the strategic template Yatsen is trying to copy with its 2022–25 skincare pivot. The judgment call is whether the multi-brand portfolio can earn the same operating leverage as Proya's single-brand focus, without losing the multi-brand-house premium that justifies the higher-than-peer R&D bill.
The Right Peer Set
Yatsen sits in two distinct comparator universes, and reading only one produces the wrong answer. The global multinationals (Estée Lauder, Coty, Shiseido) are the brands Yatsen is taking share from inside the Chinese consumer's basket — they are visibly weakening here (EL FY25 net loss US$1.13B, COTY FY25 net loss US$381M, Shiseido FY25 China & Travel Retail down 5pts to 35.3% of sales with second-consecutive net loss). The Chinese A-share and HKEX domestic set (Proya, Yunnan Botanée, Mao Geping) competes for the same Tmall/Douyin shelf-space, KOLs, and per-capita wallet. e.l.f. Beauty (US) is included as the closest archetype match — mass color, DTC-first, ~70% gross margin — because it shows what Yatsen's P&L can look like at scale when marketing intensity is held to 25% of revenue. Ulta is a demand-side adjacency, not a brand peer.
Reporting currencies differ across the row — see column three. The USD sibling normalises monetary fields to dollars.
On data confidence. Proya market cap is sourced from web research (~US$3.54B in mid-2026; Yahoo and stockanalysis.com pages returned errors during structured peer-valuation collection, so the underlying line is medium confidence; FY revenue ¥10,597M and FY period-end 2025-12-31 are from primary filing data and are high confidence). All other peer rows reconcile to Yahoo Finance key-statistics pulls dated 2026-05-08 to 2026-05-11; see data/competition/peer_valuations.json for sources and unavailable_reason per row. The Chinese A-share, HKEX, and KRX peers do not have full historical financials in this run (Fiscal.ai coverage is US/UK-centric); their FY revenue and valuation metrics are populated from filings and Yahoo, but multi-year time series for Proya, Yunnan Botanée and Mao Geping are not available within this tab.
Takeaway: gross margin alone does not earn the multiple — YSG has the second-highest gross margin in the set but the lowest EV/Revenue. What the market pays for is the combination of high gross margin AND low marketing intensity. Mao Geping has both (84% GM, 35% S&M, 20% op margin → 5.4× EV/Revenue). YSG has only the gross margin.
Where The Company Wins
Yatsen has four concrete advantages that show up in its filings and in the contrast with peer disclosure.
The most under-appreciated of these is R&D intensity. Yatsen is reflexively coded as a "Douyin marketing brand" because of the 66% S&M ratio, but it spends a higher share of revenue on research than any peer in the table — a multiple of what Estée Lauder spends, and roughly 3× e.l.f.'s line. Galenic and DR.WU sell against clinical-claim peers (CeraVe, La Roche-Posay, Skinceuticals) where regulatory and efficacy filings determine shelf access. This is what enables a ¥980 Galenic vitamin C concentrate to sit on the same prestige shelf as the multinational incumbents, and why the FY2025 skincare segment grew 63.5% YoY while color cosmetics grew only 1.9%.
Where Competitors Are Better
Four areas where peers earn a structurally better return on the same Chinese consumer.
Takeaway: the lower the red bar (S&M intensity), the higher the green bar (operating margin) — with very few exceptions. Estée Lauder is the exception (low S&M, still in the red) because of one-off China inventory write-downs, not structural. Yatsen has the longest red bar in the set. Every 200 bps of S&M deleverage drops roughly ¥85M to operating profit on the FY2025 revenue base.
The Mao Geping comparison is especially uncomfortable for the bull case. Mao Geping IPO'd on HKEX in December 2024 with one brand, one founder identity, ~¥5B revenue (similar scale to YSG), 84% gross margin (higher than YSG), 35% S&M (half of YSG's), 20% operating margin, and now trades on a 5.4× EV/Revenue and 25.6× P/E. Yatsen has spent five years and three acquisitions building a multi-brand portfolio that does not yet command the multiple of a single-brand prestige house. The strategic question is whether Yatsen's portfolio breadth is worth the operating-leverage discount, or whether the market is signalling that beauty in China is, structurally, a single-brand business.
Threat Map
Six distinct threats with named evidence and a timeline. Severity is calibrated against a 12-month investor horizon.
The two High-severity threats sit on different time horizons. Proya's premium-skincare scaling is the structural threat to Galenic/DR.WU at 6-12 months. Mao Geping's prestige-color positioning is the structural threat to the Perfect Diary trade-up funnel at 6-18 months. Platform take-rate inflation is the ongoing tax. The other threats matter for the narrative but the swing on intrinsic value runs through these three.
Moat Watchpoints
Five measurable signals to watch over the next 4-8 quarters. Each is observable in a primary source already on disk or in the next quarterly release.
The two signals that decide the next 18 months are #1 and #2 — S&M intensity and skincare mix. If skincare mix keeps climbing but S&M ratio does not fall, Yatsen is paying more to defend skincare than it once paid to defend Perfect Diary, and the thesis is mechanical not strategic. If skincare mix flatlines but S&M ratio drops, Perfect Diary has stabilised on its own and the turnaround is structural. The bull case requires both lines to move in the right direction simultaneously across at least two consecutive quarters.